Home » Phases » Early Phase Clinical Trials

Early Phase Clinical Trials

Early Phase Clinical Trials Imaging

Unlock the power of advanced imaging in early-phase clinical trials. Our team of imaging experts designs integrated, protocol-driven imaging strategies that deliver robust, objective insights into drug safety, pharmacodynamics, and early efficacy.

Early Phase Clinical Trials Imaging with DYNAMIKA™

Why DYNAMIKA™

Imaging is a powerful driver of early-phase clinical success – offering non-invasive, objective insights into drug efficacy, tissue-specific responses, and disease progression. Unlike biomarkers alone, smart imaging delivers clear evidence of mechanism-of-action and accelerates confident go/no-go decisions.

IAG ensures imaging works harder for Sponsors. Our experts design optimized imaging strategies, enforce rigorous global data quality control, and apply advanced quantitative methods – such as biomarker extraction, radiomics, and multiparametric analytics. This allows us to uncover subtle signals of efficacy and build robust, data-driven product profiles.

With IAG, Sponsors gain precise, actionable insights into a drug’s biological impact – even in small or heterogeneous cohorts – empowering faster, evidence-based development decisions and stronger pipelines.

Find Out More

Early Phase Trials with DYNAMIKA™

What You Get with Image Analysis Group

Expert Project Management and Operational Excellence

Early-phase clinical trials demand dedicated, industry-savvy project management. IAG provides experienced clinical project managers who expertly coordinate investigator site activation, imaging logistics, and regulatory documentation. Our proactive team oversees study setup, site training, and continuous QC/QA, ensuring seamless execution, timely milestone delivery, and full sponsor transparency throughout the lifecycle of your study.

Real-Time, High-Quality Imaging Data Collection

Sponsors get seamless global imaging data collection with immediate, automated quality control, ensuring data integrity and minimizing lost or unusable scans.

Rapid Support for Patient Safety

DYNAMIKA™ and our central radiology review function enables near-instant review of safety imaging, supporting timely safety assessments and fast responses to potential adverse events—critical in first-in-human trials.

Advanced Analytics and Novel Imaging Biomarkers

Move beyond conventional imaging endpoints with next-generation analytics. Our proprietary AI algorithms and advanced quantification tools extract meaningful biomarker data, uncovering early drug response signals – even in challenging, heterogeneous, or rare disease populations. Data-rich analytics support adaptive trial designs, robust go/no-go decisions, and biomarker-driven patient stratification.

Flexible Exploratory and Translational Insights

Our imaging platform enables in-depth exploratory analyses, biomarker discovery, and retrospective hypothesis testing – revealing complex phenotypes and mechanistic insights at the earliest stages. Integrated AI workflows automate image interpretation, enable deep subgroup analysis, and facilitate discovery of novel efficacy and safety markers.

Regulatory-Ready Data and Audit Trails

In early phase imaging trials, IAG delivers fully compliant data management with complete, traceable audit trails. Every imaging record is securely captured, anonymized, and documented to meet international regulatory requirements—ensuring your dataset is always inspection-ready and easily supports future filings or reviews.

Comprehensive Early-Phase Imaging Support

Our flexible, cloud-based imaging platform and expert operational team deliver:

End-to-end imaging workflow management and global site support

Imaging protocol design, regulatory submission, and imaging endpoint definition

Streamlined image data management, anonymization, and DICOM compliance

Real-time data QC, central reads, and regulatory-ready reporting

Centralized and decentralized (DCT) trial support

DYNAMIKA™ Steps

Five-Step Process to Early Phase Clinical Trial Imaging Success

Working with our team and getting started with DYNAMIKA™ should feel effortless:

1. Discovery & Study Design Collaboration

Partnering to define imaging endpoints, protocol requirements, and regulatory deliverables, enabling a solid foundation for study success.

2. Site Selection, Onboarding, and Training

Global imaging site identification, qualification, and hands-on DYNAMIKA™ training ensure standardized image acquisition and compliance.

3. Platform Configuration & Workflow Testing

Customizing upload processes, real-time QC systems, and performing test uploads to ensure seamless go-live.

4. Go-Live & Real-Time Data Collection

Sites upload images directly to DYNAMIKA™, benefiting from automated compliance checks and swift, high-quality data flow.

5. Ongoing Support, Analytics, and Scale

Continuous operational, technical, and scientific support — scaling analytics as your trial grows from startup to submission.

Early Phase Clinical Trials Case Studies

Case Study: Accelerating Oncology Drug Decisions with AI-Driven Imaging

A biotech company leveraged IAG’s DYNAMIKA™ platform for a phase I/II brain tumor trial. By automating data collection and real-time QC, image acceptance rates improved by 40% – cutting rescan requests and saving over two weeks in patient enrollment cycles. With IAG’s advanced AI analytics, the sponsor identified early efficacy signals in just 30% of expected cohort size, reducing time to interim decision by three months. This allowed rapid expansion decisions and a confident regulatory submission, directly shortening the overall early phase clinical trials timeline and reducing costs.

Case Study: Streamlining Patient Safety in Immunology Trials

In a multi-site immunology trial, IAG’s immediate imaging QC on DYNAMIKA™ enabled detection and reporting of adverse imaging findings within 24 hours for 100% of cases. Previously, such reviews could take up to a week. This fast turnaround improved patient safety monitoring and enabled the sponsor to adapt protocols in real time. Overall, the use of centralized, audited imaging workflows resulted in a 25% decrease in protocol deviations and a 20% increase in patient retention due to safer, more responsive trial management.

Case Study: Enriching Trial Populations and Reducing R&D Spend in Rare Disease

A sponsor developing a rare musculoskeletal therapy used IAG’s platform to stratify patients via quantitative MRI biomarkers and AI-based sub-grouping. This approach enriched trial cohorts with likely responders, increasing observed treatment effects by 35% and halving the sample size needed for statistical significance. The trial’s operational costs dropped by 30% compared to traditional designs, and the company secured additional funding two quarters earlier than projected, thanks to robust, regulator-ready efficacy data.

Case Study: Seamless Scale-Up: Advancing a Bone Health Therapy from Early to Late Phase Using DYNAMIKA™

A biotech company developing a novel bone health therapy seamlessly advanced from early to late phase trials by partnering with IAG and leveraging the DYNAMIKA™ platform. In phase I, IAG supported the sponsor by configuring DYNAMIKA™ to collect and centrally store DXA and X-ray images from a global network of sites, providing real-time QC and rapid site support. This ensured baseline patient selection was accurate and imaging endpoints were standardized. As the trial moved into phase III, the same platform enabled the sponsor to expand to over 50 sites across Europe and enroll more than 1,200 patients while maintaining data quality and compliance. DYNAMIKA™ reduced the time from image upload to QC report to just 0.4 days, and from QC report to final report to 2.2 days—accelerating both interim analyses and regulatory submissions. With automated workflows and integrated analytics, patient eligibility and efficacy results were available faster, streamlining trial operations and decision-making. Critically, by using DYNAMIKA™ throughout all phases, the sponsor achieved up to a 35% reduction in trial budget and completed recruitment ahead of schedule. IAG’s platform delivered full scalability, unparalleled data traceability, and regulatory readiness from first-in-human studies through to registrational submissions, markedly increasing the likelihood of both regulatory success and investor confidence

Trusted Imaging Partner

We ensure end-to-end oversight and trusted expert support from the design of your trial protocol and launching to the final database lock and data discussions. Whether you’re planning a basket or umbrella trial, unsure about the number of arms or cohorts, or anticipating your Phase 1 may advance to a pivotal study, our experts are here to help you navigate every scenario with confidence.

Collect and Hold

Budget friendly Collect and Hold solution for your trial.

Collect and Hold

Late Phase Trials

Global pivotal studies with harmonized acquisition and independent central reads that deliver regulator-ready endpoints.

Late Phase Trials

RWE & AI Studies

Real-world evidence integration and AI-powered radiomics that extend the scientific value of your imaging dataset.